Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Pulmonx Corp (LUNG) USD0.001

Sell:$56.47 Buy:$56.83 Change: $2.83 (5.24%)
Market closed |  Prices as at close on 26 February 2021 | Switch to live prices |
Change: $2.83 (5.24%)
Market closed |  Prices as at close on 26 February 2021 | Switch to live prices |
Change: $2.83 (5.24%)
Market closed |  Prices as at close on 26 February 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Pulmonx Corporation is a commercial-stage medical technology company. The Company is focused on providing planning tools and treatments for obstructive lung disease. Its solutions include Zephyr Valve, Chartis Pulmonary Assessment System and StratX Lung Analysis Platform. The Company's solutions offer minimally invasive treatment option for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). Its solution provides bronchoscopic lung volume reduction without surgery. The Zephyr Valves are indicated for bronchoscopic treatment of adult patients with hyperinflation associated with severe emphysema in regions of the lung that have little to no collateral ventilation. The Zephyr Valves are placed in the airways to occlude the diseased parts of the lung, allowing trapped air to escape.

Contact details

700 Chesapeake Dr
United States
+1 (650) 3640400

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$1.96 billion
Shares in issue:
35.67 million
Health Care Supplies
United States
US dollar

Key personnel

  • Dana Mead
    Chairman of the Board
  • Glendon French
    President, Chief Executive Officer, Director
  • Derrick Sung
    Chief Financial Officer
  • Sri Radhakrishnan
    Chief Technical Officer
  • Beran Rose
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.